



T | +61 3 5339 0704
E | info@idxgroup.com.au

Suite 9.02, Level 9,
45 William Street
Melbourne Vic 3000

www.integraldiagnostics.com.au

ASX & MEDIA RELEASE

Successful Completion of Retail Entitlement Offer

Not for release or distribution in the United States

17 March 2022, Melbourne

Integral Diagnostics (IDX) is pleased to announce the successful completion of its 1 for 7.75 pro rata accelerated non-renounceable entitlement offer (**Entitlement Offer**) announced on Wednesday, 23 February 2022.

The retail component of the Entitlement Offer (**Retail Entitlement Offer**) closed on Monday, 14 March 2022, raising approximately \$47 million. This follows the successful completion of the institutional component of the Entitlement Offer on Friday, 25 February 2022, which raised approximately \$43 million.

Applications for approximately 5.4 million new ordinary shares in IDX (**New Shares**) were received under the Retail Entitlement Offer from eligible retail shareholders, raising approximately \$18.6 million at the offer price of \$3.44 per New Share. This represents a take up rate by eligible retail shareholders of approximately 40%. Applications under the Oversubscription Facility were approximately 1.2 million New Shares (approximately \$4.2 million), increasing the total take up from eligible IDX retail shareholders to \$22.8 million (representing a total take up rate of approximately 49%). Approximately 7.0 million New Shares that were not taken up by eligible retail shareholders in the Retail Entitlement Offer will be allocated to the sub-underwriters of the Entitlement Offer.

Commenting on the outcome of the Entitlement Offer, Dr Ian Kadish, Managing Director and CEO of Integral Diagnostics, commented, "We are extremely pleased with the strong support received from our shareholders in response to the Entitlement Offer and acquisition of Peloton Radiology. We thank our investors for their continued support of IDX."

Each New Share to be issued under the Retail Entitlement Offer will rank equally with existing IDX shares on issue but will be issued after the dividend record date and will not be eligible for the interim 1H FY22 dividend of 4 cents per share. New Shares under the Retail Entitlement Offer are expected to be allotted on Monday, 21 March 2022 and are expected to trade on the ASX on a normal settlement basis on Tuesday, 22 March 2022. Holding statements are expected to be despatched on Wednesday, 23 March 2022.

Notice of Change of Exercise Price of Options under Listing Rule 3.11.2

The terms of IDX's options provide for an adjustment in their exercise price upon completion of a pro rata rights issue, such as the Entitlement Offer. The adjustment to the exercise price is determined according to the formula in ASX Listing Rule 6.22.2.

In accordance with ASX Listing Rule 3.11.2, IDX confirms the following adjustments to the exercise price of its options:

Number of Options	Expiry Date	Current Exercise Price	Adjustment	Adjusted Exercise Price
505,202	2 September 2029	\$2.7100	\$0.0514	\$2.6586
258,428	2 September 2030	\$3.9083	\$0.0514	\$3.8569
96,758	6 September 2031	\$4.9610	\$0.0514	\$4.9096

The exercise price adjustment will take effect on Thursday, 24 March 2022.

For further details contact

Integral Diagnostics

Kirsty Lally

M: +61 402 094 569

Authorised for lodgement by the Managing Director and CEO, Dr Ian Kadish

About IDX:

Integral Diagnostics (IDX) is a leading provider of medical imaging services across Australia and New Zealand. The Company provides state of the art diagnostic services to patients and their referrers at 71 radiology clinics, including 29 comprehensive sites. IDX employs some of Australasia's leading radiologists and nuclear medicine specialists in a unique medical leadership model that ensures quality patient care, service and access. Good medicine is good business. For more information, please visit www.integraldiagnostics.com.au/.

Important Notices

NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES

This announcement is not financial product advice and has not taken into account your objectives, financial situation or needs. This announcement has been prepared for release in Australia. This announcement does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States or in any jurisdiction in which such an offer would be illegal. The New Shares have not been, nor will be, registered under the U.S. Securities Act of 1933 (the Securities Act) or the securities laws of any state or other jurisdiction of the United States. Accordingly, the New Shares may not be offered or sold, directly or indirectly, to any person in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable U.S. state securities laws.